Lipocalins represent the most important protein family of the mammalian respiratory allergens.
Introduction:
Analyses over the last 2 decades have revealed that most allergens can be grouped into a few families of proteins (1) . One such family is made up of lipocalins. These are amongst the most important inhalant animal allergens. As far as their functions in their host of origin are concerned, these, depending on the lipocalin involved, include a number of properties such as pheromone transport, prostaglandin synthesis, retinoid binding, odorant binding and cancer cell interactions (1) . Lipocalins are small proteins, usually composed of less than 200 amino acids. In spite of their shared ability to act as allergens they have limited sequence homology with each other, even as low as 20%. Yet for the lipocalins whose structures have been solved, they have a common tertiary structure consisting of an 8 stranded antiparallel beta barrel with a hydrophobic ligand binding pocket (2) . Human sensitization has been identified against lipocalins from cows, guinea pigs, horses, cats, mice, rats(3) and several arthropods (4) . Human sensitization to dogs and cats is a known major risk factor for the development of asthma and allergic rhinitis. Because the prevalence of allergic disease to furry animals unfortunately continues to increase worldwide(5-7) it will be useful to expand our knowledge of the structure and function of the lipocalins that are most often involved in such human diseases.
Four of the 7 named dog allergens, Can f 1, Can f 2, Can f 4, and Can f 6, are lipocalins, though their ligands and biological functions are poorly defined. One study of patients who were sensitized to unfractionated dog dander showed that variable numbers of the patients had IgE binding the different dog allergens, ranging from 64% allergic to Can f 1 to 27% allergic to Can f 3 (8) . Symptoms from patients when exposed to dogs range from those of asthma to no symptoms at all, with percent responses depending to some extent on the dog allergens to which the sensitized individuals were exposed (9) .
In the studies described here we chose to focus on one of the dog lipocalin allergens, Can f 6. Recent reports suggests that Can f 6 is a key lipocalin responsible for allergic symptoms (10) .
Responses to Can f 6 are present in between 38%(11) and 56.3%(12) of dog sensitized individuals and Can f 6 allergic individuals are more likely to suffer from allergic rhinitis symptoms at a rate of 86% vs non-sensitized at 53% and those with asthma symptoms are found to be sensitized at 64% vs 38% in non-sensitized (10) . Therefore, Can f 6 is a major allergen driving disease amongst those people who are allergic to dogs. Moreover, in some individuals, antibodies to the cat lipocalin, Fel d 4, and/or the horse lipocalin, Equ c 1, cross react with Can f 6 suggesting some structural and sequence similarities between the 3 lipocalins (11, 13) . Since mouse Mus m 1 cross reacts with Equ c 1 (14) , it is likely that there is also cross reactivity with Can f 6. Although the structure for Fel d 4 is unknown, the ones for Equ c 1 (15) and Mus m 1 (16) are, so a comparison of the structures of Equ c 1 and Mus m 1 with Can f 6 might reveal the reasons for their immunological cross reactivity.
Here the structure of the clinically relevant Can f 6 allergen was determined at 2 Å (Table 1) resolution along with human antibody binding data that shows its biologic activity. Although structurally similar to other dog lipocalins, Can f 6's primary sequence is more similar to other mammalian lipocalins. Unique regions in the capping region and shape of the ligand binding pocket may play a role in ligand recognition, binding, and ultimate function in vivo. We also describe both unique and common features of Can f 6 and similar lipocalins that underlie their allergencity.
Material and Methods

Cloning, production, purification, and biochemical characterization
The cDNA sequence of Can f 6(11) was cloned with a C-terminal His 6 -tag and expressed in the periplasmic space of the Rosetta strain of E. coli, as previously described, with minor modifications (17) . Can f 6 was purified using a HisPur Ni-NTA Superflow Agarose nitrilotriacetic acid (NTA) column, followed by size exclusion on a Superdex 10/300 column (GE), and anion exchange chromatography (GE). The purified protein, Can f 6, was confirmed by Matrix Assisted Laser Desorption Ionization time-of-flight/mass spectrometer (MALDI TOF/MS) using the ThermoScientific LTQ Orbitrap Velos Pro mass spectrometer.
Measurements of the thermal stability of Can f 6 were made using an Agilent Stratagene MX3005P qPCR thermal shift assay as previously described (17) . Briefly, the fluorescence of Sypro Orange was monitored as temperatures were increased, leading to unfolding of the Can f 6 protein.
Crystallization
Purified recombinant Can f 6 at 15mg/ml was buffer exchanged into 10mM Tris pH 8 and 100mM NaCl. Initial crystallization trials were undertaken at room temperature using the mosquito LCP Nanoliter Protein crystallization robot. Crystals were grown and further optimized by the hanging drop vapor diffusion method containing a reservoir solution of 6% v/v 2-propanol, 0.1M sodium acetate trihydrate pH 4.5, and 26% v/v polyethylene glycol monomethyl ether 550.
Data collection, structure determination and refinement
Can f 6 crystals were harvested and cryoprotected in a reservoir solution containing 35% PEG 500 MME followed by storage in liquid N 2 . Data were collected on a single crystal at the NE-CAT 24-ID-C beam line Advanced Photon Source, Argonne National Laboratory. Data were processed in XDS Aimless and further analyzed in Phenix Xtriage (18) .
Structural determination
The structure of Can f 6 was determined by molecular replacement in Phaser (19) using Can f 4 (PDB ID: 4ODD) (20) as an initial search model. The resulting solution was further modelled and refined in the CCP4(21) suite of programs using Coot and Refmac. Phenix Validation and Refine (18) were used to confirm the final structure. The crystal packing of Can f 6 was analyzed in PISA (22) and its secondary structure was analyzed in STRIDE (23) . See Table 1 for data and refinement statistics. Pymol was used for analysis of the structure and to generate figures (24) . The atomic coordinates and the structure factors have been deposited in the RCSB Protein Data Bank with accession code 6NRE.
The amino acid residues of the ligand-binding sites and the volumes of the central cavities were determined using CASTp (25) and Voidoo(26) was used to generate a cavity volume map and visualized as Connolly surfaces (27) . Post-translational modifications were analyzed with NetNGlyc 1.0 server(28) for potential N-glycosylated sites, NetOGlyc 4.0 server was used to predict GalNAc O-glycosylation sites(29), NetPhos 3.1 Server(30) was used to predicted phosphorylation sites, and Sulfinator(31) was used to predict tyrosine sulfation.
Sequence alignments for Can f 6, Can f 2, Can f 4, Fel d 4, Equ c 1, and Mus m 1 was performed in Clustal Omega (32) . Superpositions of Can f 6, Can f 2 (PDB ID: 3L4R), Can f 4 (PDB ID: 4ODD), Equ c 1 (PDB ID: 1EW3), and Mus m 1 (PDB ID: 1QY0) were performed using Coot and Pymol.
Detection of Human Antibody Binding by ELISA
Patients' sample data were downloaded from the National Jewish Health Research Database, Data Set Identifier: 473-06-20-2018. Human serum samples banked by National Jewish Health under IRB approved protocol were retrieved after IRB approval. Sera from 5 patients who had dog IgE >5 kU/L (ImmunoCAP; Phadia, Uppsala Sweden) and skin prick testing >3x3mm to AP dog extract were selected at random for analysis. Sera from 5 age matched controls who had IgE<0.35 kU/L and negative skin testing were then selected from the biobank. For detection of biological activity by ELISA, plates were coated with recombinant Can f 6 at 50 μg/ml overnight at 4 o C and then incubated with serially diluted sera. Bound IgE was detected using alkaline phosphatase-conjugated goat anti-human secondary antibodies (A18796, Invitrogen) followed by incubation with p-nitrophenyl phosphate and measurement by spectrophotometry. The average baseline background OD405nm was subtracted from all samples and readings from the 1:10 dilution was used for analysis of significance using an unpaired t-test.
Results and Discussion
Overall structure of Can f 6
The recombinant Can f 6 crystallized in space group P3 1 2 1 with one monomer in the asymmetric unit (ASU) and was refined to a resolution of 2.06 Å. Final refinement and model statistics are in Table 1 . The overall architecture of Can f 6 contains a highly conserved lipocalin fold of an 8 stranded anti-parallel β-barrel enclosing a central ligand binding cavity core, a four-turn Cterminal α-helix that packs against the β-barrel, and a short 9th β-strand (β I ) at the C-terminus (Fig. 1A) . The top open end of the β-barrel, which marks the entrance to the presumptive ligand-binding cavity, is comprised of four β-hairpin turns. The other side of the β-barrel is closed by one β-hairpin turn, two smaller β-hairpin turns, and an N-terminal coil (Fig. 1A ). There is a disulfide bond between residues Cys69 and Cys162 that connects the C-terminal part of the protein to the central β-barrel. Three lipocalin Structurally Conserved Regions (SCRs) are present ( Fig. 1A and B ) that contain conserved residues. The SCRs hold together the N-and C-terminus of the overall fold ( Fig. 1A) under the ligand cavity calyx. By comparison, the cavity cap and calyx are more distinct in sequence and conformation when considered across all lipocalins. For example, in the structures of the lipocalins apo, holo Retinol-binding protein (RBP) (33) and apolioprotein M (34), the ligand cap conformations are different and have a more open architecture than the ligand cavity cap described here. Other residues in the SCR also form numerous non-covalent interactions. (C) Purified Can f 6 was assayed by Thermofluor shift to demonstrate the stability of our recombinant Can f 6. The Tm is 67.9 o C with standard deviation of 1.7 o C Can f 6 crystalized as a monomer reflecting its behavior during purification and on size exclusion chromatography at pH 8. The protein is quite stable to heat (Fig.1C ) which is perhaps helped by the disulfide bond and the interactions of the SCR. PISA analysis of the crystal lattice packing around the Can f 6 monomer reveals 3 adjacent lattice packing molecules. The largest packing surface, at symmetry operator position Y, X, -Z, forms a dimer buried surface area of 736 Å 2 ( Table 2 ). The dimer interface is the same as one of the dimers observed in the other deposited structure of Can f 6 (PDB ID: 5X7Y) which forms a tetramer in the ASU.
Interface surfaces of less than 1000 Å 2 between monomers can be classified as having weak transient interactions (35) . The PISA analysis of the Can f 6 crystal did not reveal any specific interactions that might result in the formation of a stable quaternary structure in solution (22) . The dimeric interface of the Can f 6 structure is considered below that for the complexation criteria. However, the dimeric crystal packing interface consists of 27 residues and 14 hydrogen bonds from each monomer ( Table 2 ) and as such would be susceptible to changes in pH conditions during purification and crystallization.
To date, lipocalin structures reveal buried interface surfaces that vary considerably from 390-23475 Å 2 (35) as dimers, trimers, or tetramers without a consistent quaternary pattern. The crystal lattice packing of Can f 6 does not resemble those observed in the structures of Can f 4 (20) nor Equ c 1 (15) . In the Can f 4 structure there is a dimer interface (largest interface 640 Å 2 ) (20) . Similarly, in the Equ c 1 structure there is also a dimer interface of (interface 1070 Å 2 )(15). In the structure of Mus m 1 the dimer interface is much smaller (interface of 389 Å 2 )(35).
The packing interfaces in the lipocalin structures may be physiologically relevant or may simply be a consequence of crystallization conditions. Differences in the monomeric and transient multimeric states of lipocalins are theorized to contribute to a protein's allergenicity and are likely unique to each allergen (4) . For example, the dimerization of the lipocalin allergen Bet v 1 has been demonstrated to increase allergenicity in skin tests of allergic mice compared to monomers (36) . However, the role of multimerization in allergenic lipocalins is inconsistent. It is not known if Can f 6 forms multimers in solution at different pH conditions as reported for other lipocalins (35) .
Comparison of the structure and sequence of Can f 6 with those of other mammalian lipocalins
Some members of the lipocalin family have limited sequence homology with each other. For example, of the known dog lipocalins, Can f 2 is only 21% identical to Can f 4 and likewise Can f 6 is 25% identical to Can f 2 and 29% identical to Can f 4 ( Fig. 2A and 3 ). On the other hand, Can f 6 is 66%; 57%; and 47% identical to the cat lipocalin, Fel d 4; the major horse allergen, Equ c 1; and the mouse lipocalin Mus m 1 respectively ( Fig. 2B and 3 ). Cross reactivity with IgE antibody binding has been show between Can f 6, Fel d 4 and Equ c 1 (11) as well as between Equ c 1 and Mus m 1 (14) which would also suggest that Can f 6 and Mus m 1 would also cross react. (Fig. 4) . The main structural differences are the β-strand turns and the folds preceding the C-terminal helices. For example, secondary structure analysis (23) of the lipocalins here, reveals that only Can f 2 has a short 3 10 helix (res 124-126) preceding the C-terminal α-helix (Fig. 2) whereas the differences in secondary structures of the other lipocalins likely interfere with 3 10 helix formation. In Can f 6, Can f 4, and Equ c 1, the equivalent region is a turn towards the C-terminal α-helix. In both Can f 6 and Equ c 1, the turn has a Pro in β F (127 in Can f 6 and 143 in Equ c 1) that stacks against a Tyr in β A (22 in Can f 6 and 38 in Equ c 1). Pro127 stabilizes this turn via a backbone carbonyl hydrogen bond to the side chain of Arg159 (Arg175 in Equ c 1). By comparison Can f 4, has a β F Gly120 and Ala121 that packs against the β A Lys16. However, it is unclear if these conformational differences are normally occurring or due to crystal packing observed in the lattice. m 1 (brown) . The overall architecture of lipocalins is highly conserved with a β-barrel that encloses a hydrophobic core. The major differences are outside the core.
Fig. 4. Structural overlay of Can f 6 (yellow) on Can f 2 (red) and Can f 4 (grey) Equ c 1 (purple), and Mus
Although lipocalins are of similar size (Table 3 and Fig. 2) , the residue differences mean they do not necessarily have a similar overall charge, immunogenic sites, nor post translational modification patterns. Predicted post translational modifications are shown ( Fig. 2 and 5) . The predicted N-linked glycosylation pattern for Can f 6 is different when compared to the other dog lipocalins here ( Fig. 2 and 5) . Two of the predicted N-linked glycosylation sites (38) of the immunologically cross-reactive Can f 6, Fel d 4, and Equ c 1 are at the similar sites, but are not present in Mus m 1 (Fig. 5B) . Recombinant Can f 6 was expressed in E. Coli and was not phosphorylated as determined by mass spec (data not shown). However, the prediction algorithm for Can f 6 suggests numerous potential sites ( Fig. 2 and 5C ). These differences in glycosylation and phosphorylation will affect lipocalin solubility, ability to bind other proteins and may also be an important feature of antibody recognition and lipocalin immunogenicity. Glycosylation and phosphorylation may mask or alter the surface features of nearby residues (39) . For example, Mouse mAb 65 recognizes the natural glycosylated Equ c 1 and not the recombinant unglycosylated Equ c 1 (23) . Similarly, human tear lipocalins are known to be phosphorylated and changes in phosphorylation may play a role in lipocalin related diseases (38) .
Comparison of the ligand binding cavities of some lipocalins
In many cases the biologically relevant lipocalin ligands are as yet unknown. Thus close examination of the properties of their ligand binding cavities, deduced from the presence of unresolved electron density and the shape of the cavity volume in these locations, is of interest.
In the structure of Can f 6 there is unmodeled electron density inside the highly hydrophobic ligand binding cavity and a uniquely shaped volume ( Fig. 6A-C) . Since Can f 6, as described here, was expressed in the bacterial periplasm and purified in its native form, the electron density observed in the ligand pocket may be from a full or partially occupied crystallization reagent, or metabolite from the bacteria used for expression. The ligand in the cavity is not thought to be from the crystallization process because the shape is inconsistent with the Poly Ethylene Glycol (PEG) used in the crystallization conditions. In either case the ligand molecule likely has similar properties to the natural binding ligand. The central cavities of the lipocalins described here vary in size and shape reflecting differences and likely specificity for their natural ligands (Fig. 6D ). The cavity of Can f 6 has a solvent accessible surface area of approximately 132 Å 2 with a volume of 55.3 Å 3 calculated by CASTp (25) . These sizes are comparable to that of Can f 2 which has a surface area of 152.0Å 2 with a volume of 60.6Å 3 and smaller than Can f 4 which has a surface area of 158.3 Å 2 with a volume of 95.0Å 3. (Fig. 6C ).
As observed for other lipocalins, the residues of Can f 6 ligand cavity are mainly hydrophobic. A total of 17 residues from the 8 antiparallel β-barrel are involved in defining the shape of the Can F 6 ligand cavity. Twelve of the 17 amino acids that line the cavity are hydrophobic with 4 polar and 1 negatively charged residue (Table 4) . A comparison of the homologous lipocalins show little sequence conservation of the cavity except for a conserved Asn91 (Table 4 ) and highly conserved Val42, Phe93, and Leu108 (Fig. 6D) At the cavity opening of the lipocalins discussed here, L1 and L5 close the cavity entrance ( Fig.  7) . Unique to Can f 6 is His87 of L5 that closes the L1 loop over the ligand space via a hydrogen bond to the backbone carbonyl of Ser39 in L1. His87 is itself stabilized by intra L5 hydrogen bonds and L5 Asn91. The L1 lid loop is stabilized by numerous hydrogen bonds to itself and by L1 Arg41 binding to the backbone residues of the L1 3 10 helix. In contrast, Can f 2, Fel d 4, Equ c 1, Mus m 1, and other lipocalins, have a highly conserved Tyr present instead of a His (Fig. 7) . Though Tyr and His are similar, this site may be important for ligand recruitment and recognition. Nearby Asn91 and Arg41 are highly conserved within the lipocalins (Fig. 2) and alternate residues have strongly similar properties, indicating a highly conserved ligand calyx cavity capping mechanism for recognition and binding of ligands. Fig. 7 . Comparison of the cavity capping residues of lipocalins. In Can f 6, at the entrance of the calyx cavity His87 in L5 stabilizes L1 over the ligand binding mouth. Arg41 and Asp91 stabilizes His87 and the L1 loop and are highly conserved indicating a common capping mechanism between lipocalins. The His in Can f 6 is unique compared to a highly conserved Tyr that is observed in the other lipocalins reflecting a unique ligand binding mechanism. Volume map is portrayed in red as Connolly surfaces (26).
The calyx cap conformation in Can f 6, places Met40 of the L1 loop over the ligand cavity where it does not make significant internal interactions. In the other lipocalins, an L1 Phe sits over the ligand space ( Fig. 7) and these residues are thought to also be involved in ligand recognition and capture.
It is possible that the Can f 6 structure here represents a closed conformation with the unresolved internal electron density that could be a full or partial ligand. Other lipocalins have different conformations of L1 and L5. Compared to the structure of Can f 6, the structure of retinoic acid bound to RBP reveals that L1 and L5 are further apart(33) and a broader opened mouth conformation. The L1 and L5 conformation accommodates the sterol ring of the ligand while the aliphatic tail sits in the ligand cavity. However, the structure of the apo form of RBP does not have significant global changes in L1 and L5. By comparison, in the structure of the Sphingosine 1-Phosphate bound apolioprotein (34) , the L1 and L5 are more similarly oriented to that observed for Can f 6 although the L1 loop is rearranged to a more open conformation. The resulting space is filled with waters that make hydrogen bonds to the sphingosine phosphate head group. Only a fully resolved ligand bound structure will reveal whether or not that is the case.
Human IgE binds recombinant Can f 6
The ability of recombinant Can f 6 to bind human sera IgE was analyzed in 5 patients who were previously determined to be AP dog dander positive on immediate skin prick testing as well as dog dander IgE positive (>5 kU/L, median 33.4 kU/L, ImmunoCAP) ( Table 5 ). Age matched controls who were immediate skin prick test negative and IgE negative (<0.35kU/L) were identified. The frequency of qualitative IgE binding to Can f 6 in dog dander positive samples was 60% (3 out of 5 patients, p-value=0.1199) (Fig 8) . IgE reactivity verifies the antigencity of recombinant Can f 6. Although no data was available regarding symptoms with exposure, molecular component resolved testing may be more accurate in the diagnosis of dog allergy especially in the individual who tested dog dander IgE and skin testing negative but who has evidence of IgE binding to Can f 6.
In summary, the biologically active high resolution x-ray structure of Can f 6 reveals greater insights into the specific roles of critical residues involved in ligand recognition and allergenicity. Further investigation into the role of lipocalins in vivo as well as in clinical allergenic diseases are needed.
